

References

- **Abeloff , Martin (2004).**Manifestations of acute and chronic leukemias. Clinical Oncology, PP. 2824-2827.
- **Andrey L, Ghindilis AL, Pavlov AR and Atanassov PB (2003).** Immunuoassay methods and protocols. Totawa N.J. Humana Press; 12:2343-2340.
- **Arico M, Valsecchi M, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui C, Masera G, Contro V, Riehm H, Heerema N, Sallan S, Pullen J, Shuster J, Carroll A, Raimondi S and Richards S (2000).** Outcome of treatment in children with Philadelphia chromosome positive acute lymphoblastic leukemia. N Engl J Med; 342: 998-1002.
- **Ayoubi TA, Van D and Ven WJ (1996).** Regulation of gene expression by alternative promoters. FASEB Journal; 10: 453-460.
- **Bain BJ (2005).** Diagnosis and classification of acute leukemia. In: Hoffbrand AV, Catovsky D, Tuddenham EG (eds): Postgraduate Haematology. Blackwell Publishing Ltd. 5th edition, p.476-492.
- **Bao S, Wu Q, McLendon RE, Hao Y, Shi Q and Hjelmeland AB (2006).** Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature; 444: 756-760.
- **Bauer N, Fonseca AV, Florek M, Freund D, Jasza J, Bornhauser M, Fargeas CA and Corbeil D (2008).** New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs; 188 (1-2): 127-138.

- **Behm F (1990).** Morphologic and cytochemical characteristics of childhood lymphoblastic leukemia. In: Childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am; 4: 715-720.
- **Belson M, Kingsley B and Holmes A (2007).** Risk factors for acute leukemia in children: a review. Environ Health Perspect; 115 (1): 138-141.
- **Bene M, Castoldi G and Knapp W (1995).** Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia; 9: 1783-1786.
- **Benett J, Catovsky D and Daniel M (1991b).** French-American – British (FAB) Co-operative Group. Proposals for the classification of the acute leukemias. Br J Haematol; 33: 451-455.
- **Benett J, Catovsky D, Danie M, Flandin, G , Galton D , Gralnick H and Sultan C (FAB Cooperative Group) (1991a).** Proposals for the classification of acute leukemias. Br J Hematol; 33: 451-455.
- **Bhatia M (2001).** AC133 expression in human stem cells. Leukemia; 15: 1685-1688.
- **Bidlingmaier S , Zhu X and Liu B (2008).** The utility and limitation of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med; 86: 1025-1032.
- **Boivin D, Labbe D, Fontainbe N, Lamy S, Beaulieu E, Gingras D and Belivean R (2009).** The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry: 48 (18): 3998-4007.

- **Borst P, Evans R and Kool M (2000).** Early resistance to therapy during induction in childhood acute lymphoblastic leukemia. *Cancer research*; 60: 5092-5096.
- **Bould F , Steinherz P, Reyes B, Heller G, Gillio A, Small T, Brochstein J, Kernan N and O'Reilly R (1999).** Allogenic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: A single institution study. *J clin Oncol*; 17: 197.
- **Bradstock KF, Janossy G, Tidman N, Papageorgiou ES ,Prentice HG, Willoughby M, Hoffbrand AV (1981).** Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukemia. *Leuk Res*; 5:301-309.
- **Brito-Babpulla F (2003).** The eosinophils, including the idiopathic hypereosinophilic syndrome. *Br J Haematol*; 121: 203-208.
- **Brown M and Wittwer C (2000).** Flow cytometry: principles and clinical applications in hematology. *Clinical chemistry*; 46: 1221-1224.
- **Brunning R (2003).** Classification of acute leukemias. *Semin Diag Pathol*; 20(3):142-146.
- **Brunning R, Borowitz M and Matutes E (2001b).** Acute leukemia of ambiguous lineage. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, (eds). *World Health Organization classification of tumors pathology and genetics: tumors of haematopoietic and lymphoid tissues*. Lyon: IARC Press; 3: 106.

- ***Brunning R, Borowitz M and Matutes E (2001a).*** Precursor B and T lymphoblastic leukemia/ lymphoblastic lymphoma. In: Jaffe E, Harris N, Stein H, Vardiman J, (eds). World Health Organization classification of tumors, pathology and genetics: tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 3:111-115.

- ***Buhring HJ, Marxer A and Lammers R (2002).*** CD133 cluster report in leucocyte typing VII. In: White cell differentiation antigens. By: David Mason. London; Oxford University Press, p: 622.

- ***Burger B, Zimmermann M, Mann G, Kuhl J, Loning L, Riehm H, Reiter A and Schrappe M (2003).*** Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol; 21 (2): 184-188.

- ***Campana D (2003).*** Determination of minimal residual disease in leukemia patients. Br J Haematol; 121:823-838.

- ***Carroll W, Bhojwani D, Min D, Raetz E, Relling M, Davies S, Downing J, Willman C and Reed J (2003).*** Pediatric acute lymphoblastic leukemia. Haematology; (1): 102-131.

- ***Carter A, Dick A, Myer E (2009).*** CD133+ adult human retinal cells remain undifferentiated in Leukemia Inhibitory Factor (LIF). BMC Ophthalmology; 1186(10):1471-2415.

- ***Castor A, Nilsson L, Astrand-Grundstrom I, Buitenhuis M, Ramirez Z, Anderson K ,Strombeck B, Garwicz S, Bekassy A, Schmiegelow K, Lausen B, Hokland P, Lehmann S ,Juliussan G ,Johansson B, Jacobcen S (2005).*** Distinct pattern of hematopoietic

stem cell involvement in acute lymphoblastic leukemia. *Nat Med*; 11:630-637.

- **Chowdhury S, Bandyopadhyay S, Mandal C, Chandra S and Mandal C (2008).** Flow-cytometric monitoring of disease –associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukemia: a two-year longitudinal follow-up study. *BMC Cancer*; 8: 40.

- **Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, Gonzalez M, Sanchez-Garcia I (2000).** A primitive hematopoietic cell is the target for the leukemia transformation in human Philadelphia-positive acute lymphoblastic leukemia. *Blood*; 95:1007-1013.

- **Collins AT, Berry PA, Hyde C, Stower MJ, and Maitland NJ (2005).** Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Res*; 65: 10946-10951.

- **Corbeil D, Roper K, Fargeas A, Joester A, Huttner W (2001).** Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. *Traffic*; 2: 82-91.

- **Cortan RS, Kumar V and Robbins SL (1999).** Robbins pathologic basis of disease. 6th ed., by: W.B. Saunders Company P. 4648-50.

- **Cortes J (2001).** Central nervous system involvement in adult acute lymphocytic leukemia. *Hematol Oncol Clin North Am*; 15: 145-162.

- **Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Cheng M, Abromowitch M, Campana D (2009).** Minimal disseminated

disease in childhood T-cell lymphoblastic lymphoma: a report from the Children's Oncology Group. J Clin Oncol; 27(21): 3533-3539.

- **Coustan-Smith E, Gajjar A, Hijiya N, Razzouk B, Ribeiro R, Rivera G, Rubnitz J, Sandlund J, Andreansky M, Hancock M, Pui C and Campana D (2004).** Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia; 18: 499-502.
- **Cox CV, Blair A (2005).** A primitive cell origin for B-cell precursors ALL. Stem Cell Rev; 1(3):189-196.
- **Cox CV, Evely RS, Oakhaill Pamphilon DH , Goulden NJ , Blair A (2007).** Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood; 109:674-682.
- **Cox CV, Diamanti P, Evely RS (2009):** Expression of CD133 on leukemia- initiating cells in childhood ALL. Blood; 113:3287-3296.
- **De Greef GE, Van Putten WL, Boogaerts M (2005):** Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON- SAKK co-operative group studies. Br J Hematol; 128:184-191.
- **Dean M, Fojo T and Bates S (2005).** Tumor stem cells and Drug resistance. Nat Rev Cancer; 5: 275-284.
- **Den-Boer M , Harms D , Pieters R , Kazemie K ,Gobel U , Korholz D , Graubner U , Haas R ,Jorch N and Spaar H (2003).** Patient stratification based on prednisolone- vincristine- asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol; 21(17): 3262-3266.

- **Dewald G and Ketterling R (2005).**Conventional cytogenetics and molecular cytogenetics in hematologic malignancies. In: Hematology: Basic Principles and Practice. By: Hoffman, R.; Benz, E.; Shattil, S. et al. (eds), 4th edition; Philadelphia; Churchill Livingstone; part 6; chapter 53, p: 979.

- **Diebold J, Jaffe E, Raphael M, Warnke R (2001).**Burkitt, lymphoma/ leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, (eds). World Health Organization classification of tumors, pathology and genetics: tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 3: 181-184.

- **Diehn M and Clarke MF (2006).**Cancer stem cells and radiotherapy: New insights into tumor radio-resistance. Journal of the national Cancer Institute; 98(24): 1755-1758.

- **Ding C and Cantor CR (2004).** Quantitative analysis of nucleic acids- the last few years of progress. Journal of Biochemistry and Molecular Biology; 37(1): 1-10.

- **Ebener U, Brinkmann A , Zotova V , Niegemann E and Wehner S (2000).**Expression of AC133 vs. CD34 in acute childhood leukemias. Klin Padiatr; 212: 90-98.

- **Ejendal KF and Hrycyna CA (2002).** Mutlidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci; 3: 503-511.

- **Elgendi HM, Mekawy MA, Abdel Waohab SE, Tawfik LM, Ismail EA and Adly AA (2010):** AC133 Expression in Egyptian children with Acute Leukemia: Impact on treatment response and disease outcome. J Pediatr Hematol Oncol; (32): 286-293.

- ***Elias J , Faderl S and Hagop M (2005).*** Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc; 80 (11): 1517-1527.
- ***Fargeas C, Joester A and Missol-Kolka E (2004).*** Identification of novel Prominin-1/ CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci; 117: 4301-4307.
- ***Fargeas CA , Corbeil D and Huttner WB (2003a).*** AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of rational nomenclature. Stem cells; 21: 506-508.
- ***Fargeas CA, Florek M, Huttner WB, Corbeil D (2003b).***Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins. Journal of Biological Chemistry; 278(10):8586–8596.
- ***Fargeas CA, Fonseca AV, Huttner WB and Corbeil D (2006).*** Prominin-1 (CD133) from progenitor cells to human diseases. Future Lipidology; 1: 213-225.
- ***Farhi D and Rosenthal N (2000).***Acute lymphoblastic leukemia. Clinics in Laboratory Medicine; 20: 17-23.
- ***Fauth F ,Weidmann E , Martin H , Schneider B , Sonnhoff S and Hoelzer D (2001).*** AC133 Expression on acute myeloid leukemia blasts: correlation to FAB and to CD34 expression and possible implications for peripheral blood progenitor cell purging in AML. Leukemia Res; 25: 191-196.
- ***Fauth F ,Weidmann E , Martin H , Schneider B , Sonnhoff S and Hoelzer D (2001).*** AC133 expression on acute myeloid

leukemia blasts: correlation to FAB and to CD34 expression and possible implications for peripheral blood progenitor cell purging in AML. *Leukemia Res*; 25: 191-196.

- **Feller N, Pol MA, Waaijman T, Weijers G, Westra G, Ossenkoppele G and Schuurhuis GJ (2005).** Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients. *Clin Cancer Res*: 11(13): 4793-4801.

- **Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti M, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancusa S and Scambia G (2008).** Expression of CD133-1 and CD133-2 in ovarian cancer. *Int J Gynecol Cancer*; 18 (3): 506-514.

- **Ferrando AA, Look AT (2003).** Gene expression profiling in T-cell acute lymphoblastic leukemia. *Semin Hematol*; 40: 274-280.

- **Florek M, Haase M, Marzesco A, Freund D, Ehninger G, Huttner WB and Corbeil D (2005).** Prominin- 1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. *Cell Tissue Res*; 319: 15-26.

- **Frater J, Yaseen N, Peterson L, Tallman M and Goolsby C (2003).** Biphenotypic acute leukemia with co-expression of CD79a and markers of myeloid lineage. *Arch Pathol Lab Med*; 127(3):356-359.

- **Freund D, Oswald J, Feldmann S, Ehninger G, Corbeil D and Bornhauser M (2006).** comparative analysis of proliferative potential

and clonogenicity of MACS-Immunomagnetic isolated CD34⁺ and CD133⁺ blood stem cells derived from a single donor. Cell Proliferation; 39(4): 325-332.

- **Friedmann A and Weinstein H (2000).** The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia. The oncologist; 5(4);321-328.
- **Gabert J, Beillard E, Van-Der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, Van Dongen JJ (2003).** Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program. Leukemia; 17(12):2318-57.
- **Gehling UM, Ergun S, Schumacher U, Wagener C, Pnatel DK, Otte M, Schuth G, Schafhausen P, Mende T, Kilic N, Kluge K, Schafer B, Hossfeld DK and Fiedler W (2000).** AC133-2, an isoform of AC133-1. Blood; 95: 3106 -3112.
- **Givan A (2001).** Flow Cytometry: First Principles. New York: Wiley-Liss. 273p.
- **Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL (2003).** Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol; 21(19): 3616-3622.

-
-
- **Gosling PT , Gemmell E , Carter CL ,Bird PS and Seymour GJ (2005).** Immunohistological analysis of *Tannerella forsythia* – induced lesions in a murine model. *Oral Microbiol Immunol*; 20: 25-30.

 - **Gowans EJ, Arthur J , Blight K (1994).** Application of in situ hybridization for the detection of virus nucleic acids. *Methods Mol Biol*; 33: 395-408.

 - **Greaves (1997).** Aetiology of Acute Leukemia. *Lancet*; 349(9084):344-348.

 - **Greaves M and Wiemels J (2003):** Origins of chromosome translocations in childhood leukemia. *Nat Rev Cancer*; 3: 639-649.

 - **Green CL , Loken M , Buck D and Deeg HJ (2000).** Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). *Leukemia*; 14(4): 770-772.

 - **Guenova M and Balatzenko G (2008).** CD133-2 (AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein. *Hematology*; 13(3):137-141.

 - **Hammond G , Sather H and Bleyer W (1997).** Stratification by prognostic factors in the design and analysis of clinical trials for acute lymphoblastic leukemia. In: *Acute leukemia VI*. T Buchner, G Schellang, W Hiddemann, D Urbanitz and J Rittert (eds), Springer-Verlag; 1: 161-208.

 - **Han X (2005).** Advances in pathological diagnosis and biology of acute lymphoblastic leukemia. *Ann Diagn Pathol*; 9(4):239-242.

- **Han X and Bueso-Ramos C (2007).** Precursor T-Cell acute lymphoblastic leukemia/ lymphoblastic lymphoma and acute biphenotypic leukemias. *American Journal of Clinical Pathology*; 528-544.
- **Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K and Barnard GF (2006).** Characterization of a side population of cancer cells from human gastrointestinal system. *Stem Cells*; 24: 506-513.
- **Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J, Lister T and Bloomfield M (2000).** The World Health Organization Classification of neoplasms of the hematopoietic and lymphoid tissues. *Hematology J*; 1: 55-60.
- **Hasle H, Heim S, Schroeder H (1995).** Transient pancytopenia preceding acute lymphoblastic leukemia (pre-ALL). *Leukemia*; 9: 605-608.
- **Hayhoe F and Flemans R (1992).** Color Atlas of Hematological Cytology. Elsevier Science Health Science div. 3rd edition. [www.amazon.com/Colour-Atlas-Haematological- Cytology-21892](http://www.amazon.com/Colour-Atlas-Haematological-Cytology-21892).
- **Hess D, Wirthlin L, Craft T, Herrbrich PE, Hohm SA and Lahey R (2006).** Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. *Blood*; 107 (5): 2162-2169.
- **Hoelzer D, Gokbuget N, Ottmann O, Pui C, Relling M, Applbaum FR, Dongen J and Szczepaski T (2002).** Acute Lymphoblastic Leukemia. *Haematology*; (1): 162-168.

- **Hong D , Gupta R , Ancliff P , Azberger A , Brown J , Soneji S ,Green J , Colman S , Piacibello W , Buckl V , Tsuzulci S ,Greaves M , Enver T (2008).** Initiating and cancer propagating cell in Tel-AML1 associated childhood leukemia. *Science*; 319:336-339.

- **Horn PA , Tesch H , Staib P , Kube D , Diehl V , Voliotis D (1999).** Expression of CD133, a novel hematopoietic precursor antigen on acute myeloid leukemia cells. *Blood*; 93:1435-1437.

- **Hurwitz CA , Loken MR , Graham ML , Karp JA , Borowitz MJ , Pullen DJ , Civin CI (1988).** Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. *Blood*; 72(1): 299-307.

- **Immervoll H , Hoem D , Sakariassen PO , Steffenson OJ and Molven A (2008).** Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. *BMC Cancer*; 8: 48.

- **Jaatinen T , Hemmoranta H, Hautaniemi, S , Niemi J , Nicorici D, Laine J, Yli-Harja O and Partanen J (2006).**Global Gene Expression Profile of Human Cord Blood-Derived CD133+ cells. *Stem cells*; 24: 631-641.

- **Jackman K , Frye C , Hunger S (2008).**Flavopiridol displays preclinical activity in acute lymphoblastic leukemia. *Pediatr Blood Cancer*; 50 (4): 772-778.

- **Jaffe E , Harris N , Stein H ,Vardiman J (2001).**World Health Organization classification of tumors, pathology and genetics: tumors

of haematopoietic and lymphoid tissues. Lyon: IARC Press; 10(12):1419-1432.

- **Jaszai J, Janich P, Farkas L , Fargeas C, Jenich P , Hasse M, Hutner W, Corbeil D (2007).** Differential expression of Prominin-1 (CD133) and Prominin-2 in major cephalic exocrine glands of adult mice. *Histochemistry and Cell Biology*; 128(5):409-419.

- **Kager L, Cheok M , Yang W, Zaza G , Cheng O , Panetta J , Pui C , Downing J , Relling M and Evans WE (2005).** Folate Pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. *J Clin Invest*; 115(1): 110-117.

- **Kamprad M , Kindler S , Schuetze N and Emmrich F (2007).**Flow cytometric immunophenotyping of umbilical Cord and peripheral blood haematopoietic progenitor cells by different CD34 epitopes, CD133, P-Glycoprotein expression and Rhodamine-123 efflux. *Transfusion Med Hemotherapy*; 34: 195-203.

- **Kania G , Corbeil D , Fuchs J , Tarasovd K , Balanchi B , Fan G , Kim J , Zhao J , Biancotti C , Hutnick I, Krueger C (2005).**Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell –derived progenitors. *Stem Cell*; 23 (6):791-804.

- **Karbanova J , Missol-Kolka E , Fonseca AV , Lorra C , Janich P , Hollerova H , Jaszai J , Ehrmann J , Kolar Z , Liebers C , Arl S , Subrtova D , Freund D Mokry J , Huttner WB and Corbeil D (2008).** The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. *J. Histochem. Cytochem*; 56(11): 977-993.

- **Katoh Y and Katoh M (2007).** comparative geneomics on PROM1 gene encoding stem cell marker CD133 International Journal of molecular medicine; 19: 967-970.
- **Kenney B , Zieske A, Rinder H, Smith B (2008).**DNA ploidy analysis as an adjunct for the detection of relapse in B-lineage acute lymphoblastic leukemia. Leuk Lymphoma; 49(1):42-48.
- **Keren A, Shafir O , Shimshoni E , Marvaud V , Bachschmidt A and Long J (2007).**Experimental estimates of dephasing time in molecular magnets. Phys Rev Lett; 98: 25-30.
- **Keren DF, McCoy JP and Carey JL (2001).**Flow Cytometry in Clinical Diagnosis 3rd edn. Chicago, III: American Society of clinical Pathology Press: 739.
- **Kersey J (1997).** Fifty years of studies of the biology and therapy of childhood leukemia. Blood; 90: 4243-4251.
- **Kim JH , Cho HI , Kim EC , Ko EK , See CJ , Park SY And Less DS (2002) .** A study on 289 consecutive Korean patients with acute leukaemias revealed fluorescence in situ hybridization detects the MLL translocation without cytogenetic initially and during follow-up.Br J Haematol; 119 (4): 930-939.
- **Kinney M and Lukens J (2001).**Classification and Differentiation of the Acute Leukemias. In: Wintrobe's Clinical Hematology. G Lee, J Forster and J Lukens (eds), 10th edition, Williams and Wilkins (A Waverly Company), Baltimore; P: 2209.
- **Kipps TJ (2006).**The cluster of differentiation antigens. In: William's Hematology. By: Lichtman, M.A.; Kipps, T.J.; Kaushansky, K.;

Beutler, E.; Seligsohn, U. and Prchal, J. (eds); 7th edition; USA: McGraw-Hill Companies, p: 183.

- ***Kitada S, Pedersen IM , Schimmer AD and Reed JC (2002).***Dysregulation of apoptosis genes in hematopoietic malignancies. *Oncogene*; 21: 3459-3474.
- ***La Barge M and Bissell M (2008).*** Is CD 133 a marker of metastatic colon cancer stem cells? *J Clin Invest*; 118 (6): 2021-2025.
- ***Lang P , Bader P and Schumm M (2004).*** Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. *Br J Haematology*; 124: 72-79.
- ***Langer C, Radmacher MD, Ruppert AS (2008):*** High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene- expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. *Blood*; 111: 5371-5379.
- ***Lee H , Im S , Kang M , Kim K , Kim S , Kim H , Kang J and Lee G (2008).***Irreversible paraplegia following one time prophylactic intrathecal chemotherapy in an adult patient with acute lymphoblastic leukemia. *Yonsei Med J*; 49(1): 151-159.
- ***Lee ST , Jang HJ , Min YH , Hahn JS and Ko YW (2001).*** AC133 antigen as a prognostic factor in acute leukemia. *Leuk Res*; 25: 757-61.

- **Levsky JM and Singer RH (2003)** .Fluorescence in situ hybridization: past, present and future. *Journal of Cell Science*; 116 (14): 2833-2838.
- **Li CW , Heidt DG , Dalerba P , Burant CF , Zhang LJ and Adsay V (2007)**. Identification of pancreatic cancer stem cells. *Cancer Res*; 67: 1030-1037.
- **Lichtman SM, Hollis D, Miller AA (2006):** Prospective evaluation of the relationship of patient age and clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). *J Clin Oncol*; 24:1846-1851.
- **Liu G , Yuan X, Zeng Z , Tunici P , Abdulkadir IR , Lu L , Irvin D , Black KL and Yu JS (2006)**. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. *Molecular Cancer*; 5: 1476-1479.
- **Lowenberg B, Griffin JD and Tallman MS (2003)**. Acute myeloid leukemia and acute promyelocytic leukemia. *Hematology*; 82: 101.
- **Lucio P , Parreira A , Van -Den Beemd MW ,Van-Lochem EG ,Van-Wering ER , Baars E , Porwit-Mac Donald A , Bojorklund E , Gaipa G , Piondi A , Orfao A, Janossy G , Van Dongen JJ , San Miguel JF (1999)**. Flow cytometric analysis of normal B-cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B- ALL. *Leukemia*; 13(3):419-427.
- **Luxton R (2000)**.Oncogenes, tumor suppressor genes and malignant transformation. In: *Progress in Hematology*: 2. C Pallister and C Dunn (eds). London chapter 5.p:107.

- **Mackay IM (2007).** Real-Time PCR in microbiology. Caister Academic Press; 12: 765-770.

- **Maeda S , Shinchu H , Kurahara H , Mataka Y , Maemura K, Sato M , Natsugoe S , Aikou T and Takao S (2008).** CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. British Journal of Cancer; 98(8):1389-1397.

- **Mahoney M , Moysich K , McCarthy P , McDonald R , Stepanenko V and Day R (2004).**The Chernobyl childhood leukemia study: background and lessons learned. Environ Health; 3(1):12.

- **Marcucci G, Caligiuri MA and Bloomfield CD (2003).** Core binding factor (CBF) in acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically. Eur J Haematol; 71(3):143-154.

- **Martens D, Smulders C , Kampschoer P, Offermans J , Engelen J , Haners A , Lammens M and Sclander-Stumpel C (2000) .** 14q terminal deletion: prenatal diagnosis in a child with severe congenital anomalies. Genet Couns; 11: 341-44.

- **Marti GE , Stetler-Stevenson M , Bleasing JJ , Fleisher TA (2001).**Introduction to Flow Cytometry. Seminars in Hematology; 38(2):93-99.

- **Mascarello JT , Brothman AR , Davison K, Cooley LD, Dewald GW , Herrman M , Park JP , Persons LD , Rao KW , Schneider NR , Vance GH (2002).** Proficiency testing for laboratories performing fluorescence in situ hybridization with chromosome-specific DNA probes. Arch Pathol Lab Med; 126:1458-1462.

- **Mathieu T, Cédric ST, Sabine H, Peter DA, Josée H, Claude P and Trang H (2010).** Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. *Genes and Development*;12:25-27

- **Maw MA , Corbeil D , Koch J , Hellwing A , Wilson-Wheeler JC , Bridgesw RJ , Kumaramanickavel G , John S , Nancarrow D , Roper K , Weigmann A , Huttner WB and Denton MJ(2000).** A frame shift mutation in prominin (mouse)-like 1 causes human retinal degeneration. *Hum Mol Genet*; 9: 27-34.

- **McCoy JP (2002).**Basic principles of flow cytometry. *Hematol Oncol Clin North Am*; 16: 229-243.

- **Mckenna RW (2000).** Multifaceted approach to the diagnosis and classification of leukemia. *Clinical chemistry*; 46(8)(B) : 1252-1259.

- **MeEvoy C, Morley A and Firgaira F (2003).** Evidence of whole chromosome 6 loss and duplication of the remaining chromosome in acute lymphoblastic leukemia. *Genes,Chromosomes and Cancer*; 37 (3): 321-325.

- **Mehra N, Penning M , Mass J , Laurens V , Carla H (2006).** Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. *Clinical Cancer Research*; 12: 4859-4866.

- **Mesiwala AH , Scampavia LD , Rabinovitch PS , Ruzicka J, Rostomily RC (2004).** On-line flow cytometry for real-time surgical guidance. *Department of Neurosurgery*; 55(3): 551-60.

- **Meyer-Monard S , Parlier V , Passweg J , Muhlematter D , Hess U , Bargetzi M , Kuhne T , Carbol C , Gratwohl A , Jotterand M and Tichelli A (2006):** Combination of broad molecular screening and cytogenetic analysis for genetic risk assignment and diagnosis in patients with acute lymphoblastic leukemia. *Leukemia*; 20(2): 247-253.

- **Miraglia S , Godfrey W , Yin AH , Atkins K , Warnke R , Holden J (1997).** A novel five transmembrane hematopoietic stem cell antigen: isolation, characterization and molecular cloning. *Blood*; 90:5013-5021.

- **Mizrak D, Brittan M and Alison MR (2008).** CD133 molecule of the moment. *J. Pathol.*; 214 (1): 3-9.

- **Morrison C (2006).** Fluorescent in situ hybridization and array comparative genomic hybridization: complementary techniques for genomic evaluation. *Arch Pathol Lab Med*; 130(7): 967-974.

- **Neuroscience N (2005).** Fluorescence in situ hybridization. *Nature Methods*; 2: 237-238

- **Oconnor S and Boneva R (2007).** Infectious Etiologies of childhood leukemia: Plausibility and challenges to proof. *Environ Health Perspect*; 115(1):146-148.

- **Okamoto O , Carvalho A , Marti L , Vencio R , Moreira-Filho C (2007).** Common molecular pathways involved in human CD133/CD34 positive progenitor cell expansion and cancer *Cell International*; 7:11-13.

- **Olsen RJ , Chang C , Herrick JL , Zu Y and Ehsan A (2008).** Acute leukemia immunohistochemistry: A systematic diagnostic approach. Arch Pathol Lab Med; 132: 462-475.

- **Orfao A, Schmitz G, Brando B , Ruiz-Arguelles A , Basso G , Braylan R , Lacombe F , Rothe G , Lanza F , Papa S , Lucio P , San Miguel J (1999).** Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future direction. Clinical Chemistry; 45: 1708-1717.

- **Ormerod MG (2001).** Using flow cytometry to follow the apoptotic cascade Redox Rep; 6 (5): 275-87.

- **Paraskevas F (2004).** Clusters of differentiation. In: Wintobe's Clinical Hematology. By: Greer, J.; Foerster, J.; Lukens, J.; Rodgers, G.; Paraskevas, F. and Glader, B. (eds); 11th edition; USA; Lippincott Williams and Wilkins Publishers, p:79.

- **Paternoster SF , Brockman SR , McClure RF , Remstein ED , Kurtin PJ , Dewald GW (2002).** A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol; 160: 1967.

- **Peichev M , Naiyer J , Pereira D , Zhu Z, Lane W (2000).** Expression of VEGFR-2 and AC133 by circulating human CD34 positive cells identifies a population of functional endothelial precursors. Blood; 95: 952-958.

- **Perentesis J (1997).** Why is age an important independent prognostic factor in acute lymphoblastic leukemia. Leukemia; 11:4-12.

-
- **Phillips TM , McBride WH and Pajonk F (2006).**The response of CD24-/low /CD44+ breast cancer –initiating cells to radiation. J Nat Cancer Inst; 98: 1777-1785.
 - **Pieters R , Carroll W (2008).** Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am; 55 (1): 1-7.
 - **Plasschaert SL , Kamps WA, Vellenga E , De Vries EG, De Bont ESJM (2004).** Prognosis in childhood and adult acute lymphoblastic leukemia: a question of maturation? Cancer Treatment Reviews; 30:37-51.
 - **Pollock B , DeBaun M , Camitta B , Shuster J , Ravindranath Y , Pullen J , Vita JL , And V , Mahoney D , Lauer S , Murphy S (2000).** Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol; 18: 813-823.
 - **Potapnev M , Belevsev M , Bortkevich L , Grinev V , Martsev S , Kravchuck Z and Migal N (2004).**Significance of serum IgG for leucocytosis and prognosis in childhood B-lineage ALL. Pediatr Blood Cancer; 45: 421-427.
 - **Principe MI , Del Poeta G , Venditti A , Buccisano F , Mauriello L , Mazzone C (2005).** apoptosis and immaturity in acute myeloid leukemia. Hematology; 10(1): 25-34.
 - **Pui C, Chessells J , Camitta B , Baruchel A , Biondi A , Boyett J , Carroll A , Eden O , Evans W , Gardner H , Harbott J , Harms D , Harrison C , Harrison P , Heerema N , Janka-Schaub G , Kamps W , Masera G , Pullen J , Raimondi S , Richards S , Riehm H , Sallan S , Sather H , Shuster J ,**
-

-
- Silverman L , Valsecchi M , Vilmer E , Zhou Y , Gaynon P and Schrappe M (2003a)** .Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. *Leukemia*; 17: 700-706.
- **Pui C , Relling M and Evans W (2002)** .Role of Pharmacogenomics and phamacodynamics in the treatment of acute lymphoblastic leukemia. *Best Pract Res Clin Hematol*; 15:741-756.
 - **Pui C , Relling M and Downing J (2004a)**. Acute lymphoblastic leukemia. *N Engl J Med*; 350: 1535-1548.
 - **Pui C , Cheng C , Leung W , Rai S , Rivera G , Sandlund J, Ribeiro R, Relling M, Kun L, Evans W and Melissa M, Hudson M (2003b)**.Extended follow-up of long term survivors of childhood acute lymphoblastic leukemia. *N Engl J Med*; 349: 640-649.
 - **Pui C , Sandlund J , Pei D , Rivera G , Howard S , Ribetiro R , Rubniotz J , Razzouk B , Hudson M , Cheng C , Raimondi S , Behm F , Downing J , Relling M and Evans W (2003c)**. Results of therapy for acute lymphoblastic leukemia in black and white children. *JAMA*; 290(15): 2001-2007.
 - **Pui C, Schrappe E , Ribeiro R and Niemeyer C (2004b)**.Childhood and adolescent lymphoid and myeloid leukemia. *American society of haematology*; (1): 118-145.
 - **Pui C, Pei D , Sandlund JT , Campana D , Ribeiro RC , Razzouk BI , Rubritz JE, Hijiya N, Howard SC, Jeha, S, Cheng, C, Dowing JR, Evans WE , Relling MV, Hudsong M (2005)**. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol*; (23):7936-7941.
-

- ***Pui C , Campana D and Evans W (2001).***Childhood acute lymphoblastic leukemia current status and future perspectives. *Lancet Oncol*; 2: 597-607.
- ***Pui CH Evans W (2006).*** Drug therapy: treatment of acute lymphoblastic leukemia. *N Engl J Med*; 354:166-178.
- ***Radeliff G and Jaroszeski MJ (1998).*** Basics of flow cytometry. *Methods Mol Biol*; 91: 1-24.
- ***Raimondi S, Zhou Y, Shurtleff S and Rubnitz J (2006).***Near-triploidy and near tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype and favorable outcome. *Cancer Genetics and Cytogenetics*; 169: 50-57.
- ***Ramos-Vara JA (2005).***Technical aspects of immunohistochemistry. *Vet Pathol*; 42: 405-426.
- ***Rappa G, Fodstad, O and Lorico A (2008).*** The stem cell-associated antigen CD133 (Prominin-1) is a molecular Therapeutic Target for Metastatic Melanoma. *Stem Cells*; 26 (12): 3008-3017.
- ***Raspadori D , Lauria F , Ventura MA , Rondelli DA , Visani G , Do Vivo A And Tura S (1997) .*** Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. *Leuk. Res*; 21 (7): 603-607.
- ***Rautonen J and Siimes M (1998).*** Elevated serum Transaminase activity at diagnosis is associated with rapidly progressing disease in children with acute lymphoblastic leukemia. *Cancer*; 61: 754-759.

- **Ravandi F and Gandhi V (2007).** Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukemia and lymphoma .Expert Opin Investig Drug;27(2):169-175.

- **Rebecca L , Brandt S and Brandt S (2004).** Molecular Biology and Hematology. In: Wintobe's Clinical Hematology; By: Greer J., Foerster J., Lukens J., Rodgers G., Paraskevas F. and Glader B. (eds); 11th edition; USA; Lippincott Williams and Wilkins publishers, P: 131.

- **Reichelt H , Barz D and Thude H (2009).** CD34+ and CD 133 + primitive stem cell expression in peripheral blood: considering gender, age, and smoking. Transfus Med Hemother; 36: 129-134.

- **Ricci-Vitiani L , Lombardi DG , Pillozzi E, Biffoni M, Todaro M Peschle C and De Maria R (2007).** Identification and expansion of human colon- cancer- initiating cells. Nature; 445: 111-115.

- **Rivera G, Zhou Y and Hacock M (2005).** Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer; 103: 368-376.

- **Rocha V, Labopin M and Sanz G (2004).** Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute lymphoblastic leukemia. N Engl J Med; 351: 2276-3485.

- **Romeo MJ , Wunderlich J, Ngo L, Rosenberg S.A, Steinberg SM, Berman DM (2006).**Measuring tissue- based biomarkers by immunochromatography coupled with reverse-phase lysate microarray. Clin Cancer Res; 12 (8): 2463-2467.

- **Roper K, Corbeil D and Huttner WB (2000).** Retention of prominin in microvilli reveals distinct cholesterol- based lipid microdomains in the apical plasma membrane. *Nature Cell Biology*; 2 (9): 582-592.
- **Sachdeva M, Ahluwalia J, Das R and Varma N (2006).** Role of FAB classification of acute leukemias in era of immunophenotyping. *Indian J Pathol Microbiol*; 49 (4): 524-527.
- **Salnikov AV, Gladkich J, Moldenhauer G (2010).** CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. *Int. J. Cancer*; 126 (4): 950–8.
- **Satake N (2006).** Acute Lymphoblastic Leukemia. www.emedicine.com/ped/topic2587.htm in Apr 6, 2010.
- **Saxena R and Anand H (2008).** Flow cytometry in acute leukemia. *Indian J Hematol & Blood Transfus*; 24 (4): 146-150.
- **Seiter K (2006).** Acute lymphoblastic leukemia. www.emedicine.com/med/topic3146.htm in Mar 10,2010.
- **Sergery V, Shmelkov L , Clair R (2004).** Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. *Blood*; 103: 2055-2061.
- **Settin A , Al Hagggar M , Al Dosoky T, Al Baz R, Abdelrazik A, Fouda M, Aref S and Al-Tonbary Y (2007).** Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia. *Indian J pediatri*; 74 (3): 255-259.
- **Sharma J and Mohindroo S (2004).** FAB classification of leukemia: a cytochemical study. *Indian J Pathol Microbiol*; 47 (3): 336-339.

- **Sonneveled P (2000).**Multidrug resistance hematological malignancies. J Intern Med; 247 (5): 521-534.

- **Stock W, Tsai T, Golden C, Rankin C, Sher D, Slovak ML and Pallavicini MG (2000):** Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood; 95:2364.

- **Strehl S (2006).** Searching for prognostic markers in childhood T-cell acute lymphoblastic markers in childhood T-cell acute lymphoblastic leukemia. Hematologica; 91: 1156-1159.

- **Styczynski J and Drewa T (2007).**Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochimica Polonica; 54 (4): 717-726.

- **Summers Y, Heyworth C , Wynter E , Hart C (2004).**AC133+ G₀ cells from cord blood show a high incidence of long-term culture – initiating cells and a capacity for more than 100 million-fold amplification of colony- forming cells in vitro. Stem Cells; 22: 704-715.

- **Tkachuk DC and Hirschmann JV (2007).** Acute leukemias. In: Wintrobe's atlas of clinical hematology, By: Tkachuk D. C. And Hirschmann. J.V.(eds), (1st Edition). Lippincott Williams & Wilkins publishers, P: 102.

- **Toedling J, Rhein P, Ratei R , Karawajew L and Spang R (2006).**Automated in-silico detection of cell populations in flow cytometry readouts and its application to leukemia disease monitoring. BMC Bioinformatics; 7: 282.

- **Tong Q , Zheng L , Tang S , Ruan Q , Liu Y, Li S , Jiang G. and Cai J (2008).** Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. *World J Pediatr*; 4 (1): 58-62.
- **Toren A , Bielora B , Jacob-Hirsch J (2005).** CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. *Stem cells*; 23:1142-1153.
- **Torrente Y, Belicchi M , Sampaolesi M, Pisati F, Mergalli M and D'Antona G (2004).** Human circulating AC133+ stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. *The journal of Clinical Investigation*; 114 (2): 182-195.
- **Uchida N, Buck DW and He D (2000).** Direct isolation of human central nervous system stem cells. *Proc Natl Acad Sci USA*; 97: 14720.
- **Van Dijk M.A, Voorhoeve P.M, Murre C (1993).** Pbx1 is converted into a transcriptional activator upon acquiring the N-terminal region of E2A in pre-B-cell acute lymphoblastoid leukemia. *Proc Natl Acad Sci U S A* 90. (13): 6061-6065.
- **Vanstijn A, Feller N and Kok A (2005).** Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis –resistant protein profile at diagnosis. *Clin Cancer Res*; 11: 2540-2546.
- **Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Lindberg EH, Tefferi A and Bloomfield CD (2009).** The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia: Rationale and Important Changes. *Blood* 209262 online 1st edition Paper, April 8, 2009.

- **Vercauteren SM and Sutherland HJ (2001).** CD133 (AC133) expression on AML cells and progenitors *Cytotherapy*; 3(6): 449-459.
- **Wagner M, Horn M , Daims H (2003) .** Fluorescence in situ hybridization for the identification and characterization of prokaryotes. *Current Opinion in Microbiology*; 6:302–309
- **Waller CF, Martens UM and Lange W (1999):** Philadelphia chromosome- positive cells are equally distributed in AC133+ and AC133-fractions of CD34+ peripheral blood progenitor cells from patients with CML. *Leukemia*; 13: 1466-1467.
- **Wang W , Wang HY , Zhao HX , Cui ZG and Li GL (2007).** Expression of CD133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome. *Zhongguo Shi Yan Xue Ye Xue Za Zhi.*; 15 (3): 470-473.
- **Wang W, Wang HY, Zhao HX , Cui ZG and Li GL (2007).** Expression of CD 133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome. *Zhongguo Shi yan Xue Ye Xue Za Ahi.*; 15 (3): 470-473.
- **Weigmann A, Corbeil D, Hellwing A and Huttner W.B (1997).** Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasma lemmal protrusions of non-epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*; 94 (23): 12425-12430.
- **Weir EG and Borowitz MJ (2001).** Flow cytometry in the diagnosis of acute leukemia. *Semin Hematol*; 38: 124.

- **Wetzlar M (2000).** Cytogenetics in adult acute lymphoblastic leukemia. *Hematol Oncol Clin North Am*; 14 (6): 1237-1239.
- **Winich N, Carrol W and Hunger S (2004):** childhood leukemia. New advances and challenges. *N Engl J Med*; 351: 601-603.
- **Wu JT (2000).**Quantitative immunoassay: A practical guide for assay establishment, troubleshooting, and clinical application. Washington D.D. APCC Press. P: 88-95.
- **Wuchter C , Ratel R , Spahn G , Schoch C and Harbott J (2001).** Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. *Haematologica*; 86-154-161.
- **Xuereb J and Blundell R (2007).** Acute leukaemia. *International Journal of Molecular Medicine and Advance Sciences*; 3(4): 138-144.
- **Yang C, Ynag Y, Gupta N, Liu X, He A , Liu L , Zuok J , Chang Y and Fang F (2007).**Pentaspan membrane glycoprotein, Prominin-1, is involved in glucose metabolism and cytoskeleton alteration. *Biochemistry (Moscow)*; 72 (8): 854-862.
- **Yin JA and Grimwade D (2002).**Minimal residual disease evaluation in acute myeloid leukemia. *Lancet*; 360 (9327) 160-162.
- **Yin S , Li J, Hu C , Chen X , Yao M , Yan M , Jiang G , Ge C , Xie H , Wan D (2007) .**CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. *Int J Cancer*; 120: 1444-1450.
- **Ying Y, Flint A , Dvorin EL and Bischoff J(2002).**AC133-2, a novel isoform of human AC133 stem cell antigen. *The Journal of Biological*; 277 (23): 20711-20716.

- ***Yoshida K , Ueno S , Iwao T , Yamasaki S , Tsuchida A , Ohmine K , Ohki R , Choi Y.L , Koinuma K , Wada T, Ota J ,Yamashita Y , Chayama K , Sato K and Mano H (2003).*** Screening of genes specifically activated in the pancreatic juice ductal cells from the patients with pancreatic ductal carcinoma. *Cancer Sci.*; 94: 263-270.

- ***Yu Y ,Flint A , Dvorin EL and Bischoff J (2002):*** AC133- 2, a novel isoform of human AC133 stem cell antigen. *The Journal of Biological Chemistry*; 277 (23): 20711-20716.

- ***Zhang L , Parkurst J , Kern W , Scott K , Niccum D and Mulvihill J (2003) .***Chromosomal changes detected by fluorescence in situ hybridization in patients with acute lymphoblastic leukemia. *Chin Med J*; 116: 1298 -1309.

- ***Zhang Q , Haleem R and Cai X (2002).***Identification and characterization of a novel testosterone – regulated prominin-like gene in the rat ventral prostate. *Endocrinology*; 143: 4788-4796.

- ***Zhou Y , Li Q , Meng HX , Wang YF , Yu Z and Qiu LG (2005).***The expression and clinical significance of early differentiation antigens in acute leukemia. *Zhonghua Nei Ke Za Zhi.*; 44 (1): 46-49.

- ***Zhou L , Wei X , Change L (2007).***CD133, one of the markers of cancer stem cells in Hep-2 cell line. *The New England journal of Medicine*; 117: 455-460.

- ***Zhou Y , Meng HX , Yu Z , Li Q , Wang YF , Mai YJ , Han JL and Qiu LG (2004).*** The expression of CD133 in acute leukemia and its clinical significance *Zhonghua Xue Ye Xue Za Zhi.*; 25 (7): 401- 404.

- ***Ziegler D , Pozza L , Waters K and Marshall G (2005).*** Advances in childhood leukemia: successful clinical trials research leads to individualized therapy. MJA; 182 (2): 78-81.